Bayer reaches agreement to postpone more glyphosate lawsuits for settlement talks

This post was originally published on this site

FRANKFURT (Reuters) – Germany’s Bayer (DE:) has agreed with plaintiffs to postpone its next two U.S. lawsuits over the alleged cancer-causing effects of its glyphosate-based weed killers to allow more time for talks on a settlement.

The company, which is facing 42,700 U.S. plaintiffs, is widely expected to eventually buy itself out of the litigation, with analysts currently estimating the size of a future settlement at $8-$12 billion.

Bayer agreed with the plaintiff to delay for about six months a case in the California Superior Court for Lake County scheduled for Jan. 15, a company spokesman said in a written statement.

A second case due to begin on Jan. 21 in the California Superior Court for Alameda County would also be postponed until a date yet to be determined.

Bayer said the postponements would provide more time for it and representatives of the plaintiffs to “engage constructively in the mediation process”.

The company, which acquired the weed killer brands last year as part of a $63 billion takeover of Monsanto (NYSE:), has ruled out pulling the products from the U.S. market, citing regulators and extensive research which have found glyphosate to be safe.

It will early next year appeal to reverse the first three U.S. court rulings that awarded tens of millions of dollars to each plaintiff.

Other trials initially scheduled for this year have already been postponed.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.